New Columbia study suggests current vaccines and monoclonal antibody therapies provide less neutralizing activity against the U.K. and South Africa variants of SARS-CoV-2.
In order to monitor and contain the spread of SARS-CoV-2 it is necessary to test large numbers of people on a regular basis in decentralized settings. Researchers of the Max Planck Institute for Evolutionary Anthropology and the Hospital St. Georg in Leipzig, Germany, have developed improved protocols for the detection of SARS-CoV-2. The method can detect a positive sample in a pool with 25 uninfected samples in less than one hour.
New research from Washington University School of Medicine in St. Louis has found that new variants of the virus that causes COVID-19 can evade antibodies that work against the original form of the virus that sparked the pandemic, potentially undermining the effectiveness of vaccines and antibody-based drugs now being used to prevent or treat COVID-19.
The treatment uses a type of CRISPR to target viral RNA and appears to stop replication of both viruses in the lungs.
The body's immune response plays a crucial role in the course of a SARS-CoV-2 infection. In addition to antibodies, the so-called T-killer cells, are also responsible for detecting viruses in the body and eliminating them. Scientists from the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and the Medical University of Vienna have now shown that SARS-CoV-2 can make itself unrecognizable to the immune response by T-killer cells through mutations.
The illegal wildlife trade is often seen as one of the major gateways to zoonotic diseases, that spread from animals to humans. While the illegal trade in tigers, ivory, rhino horn, pangolins and primates is of paramount concern for public health, Professor Nijman says the legal wildlife trade should be of equal concern.
Pancreatitis drug Camostat inhibits new SARS-CoV-2 activators identified in the upper respiratory tract
Specialists in viral and genetic analysis, led by Swiss scientists Dr. Emma Hodcroft at the University of Bern and Prof. Christophe Dessimoz at University of Lausanne, alongside Dr. Nick Goldman at EMBL-EBI in the UK, lay out the 'bioinformatics bottlenecks' that are hindering response to the SARS-CoV-2 pandemic, and propose ways to 'clear the road' for better tools and approaches.
UC San Diego School of Medicine researchers develop an automated process to test city sewage for SARS-CoV-2, allowing them to forecast the region's COVID-19 caseload one to two weeks ahead of clinical diagnostic reports.
An international research group led by the University of Basel has developed a promising strategy for therapeutic cancer vaccines. Using two different viruses as vehicles, they administered specific tumor components in experiments on mice with cancer in order to stimulate their immune system to attack the tumor. The approach is now being tested in clinical studies.